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ABSTRACT  
 
INTRODUCTION  
The Royal College of Pathologists recommend that a median of at least 12 lymph nodes 
should be harvested during pathological staging of colorectal cancer.  It is not always 
easy to harvest the required number, especially in patients with rectal cancer receiving 
neoadjuvant therapy.  
 
Lymph node revealing solutions, e.g. GEWF, may improve nodal yield.  GEWF is safe, 
cheap and easy to use. 
 
METHODS  
In a controlled trial, lymph node yields were compared after secondary specimen 
dissection following either 24 hours of further fixation in formalin (n=101) or GEWF 
immersion (n=99).  The number, size and tumour status of additional lymph nodes 
identified was compared between groups.  Twenty-seven cases which received long-
course neoadjuvant therapy were also assessed. 
 
RESULTS  
Median lymph node yield at primary dissection met national standards overall (19) but 
also in the long-course neoadjuvant therapy group (13).  Lymph nodes were smaller in 
neoadjuvant cases compared to non-neoadjuvant cases (mean size range 1.3-5.6mm 
vs 1.5-8.9mm).  The use of further fixation and GEWF detected more nodes at 
secondary dissection. The mean number of additional nodes harvested was greater with 
formalin (8.3) than GEWF (7.3).  There was no significant difference in the mean size of 
the additional lymph nodes detected between groups (point estimate 1.02; 95% CI -
0.58-2.63; p=0.211).  Upstaging triggering adjunct chemotherapy occurred in 1% 
(2/200) of cases.  
 
CONCLUSIONS 
The routine use of adjunct techniques to identify additional lymph nodes is unnecessary 
with underlying high quality dissection practice. Emphasis should be placed upon 
education and training, spending appropriate time dissecting, and ensuring specimens 
are sufficiently fixed beforehand.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Colorectal carcinoma (CRC) is the fourth most common cancer in the UK.[1]  Nodal 
metastasis is inextricably linked to the prognosis of the patient,[2-6] and just one nodal 
tumour deposit upstages the malignancy from pN0 to pN1 in the TNM system,[5] which 
has important implications when adjuvant chemotherapy is considered.[7]  High quality 
histopathological assessment includes harvesting an adequate number of lymph nodes.  
Current recommendations are that a median of at least 12 lymph nodes should be 
retrieved for adequate staging,[5-6] with all mesentery within the tumour vicinity 
searched.  This is based on evidence demonstrating the prognostic significance of 
lymph node harvesting with differing numbers of nodes retrieved.[2-5].  Some literature 
suggests that more lymph nodes should be harvested for adequate staging,[2] but 12 is 
the current consensus.[5-6] 
 
The recommended number of nodes is not always achieved, even in published studies.  
Most notably, in patients who have received long-course neoadjuvant chemotherapy for 
rectal carcinoma, the size of lymph nodes may be reduced making identification more 
challenging.[8]   Other contributory factors may include fixation time, experience of the 
surgeon and failure by the dissector to appropriately examine or identify all nodes within 
a specimen, either due to lack of experience or poor technique.[9-14].    In response to 
this, a number of studies have addressed the issue of lymph node harvesting using a 
variety of techniques,[9,15-25] including lymph node revealing solutions.[9,19-46]  
Studies using GEWF, a mixture of glacial acetic acid, ethanol, water and formalin, 
suggested that its use will identify an increased number of lymph nodes,[9,37-43,45-46] 
and that this may lead to stage migration from node negative to 
positive.[19,27,29,34,42-43]  GEWF has been shown to facilitate identification of smaller 
lymph nodes,[9,38,41,42,46] which may be especially useful for cases where 
neoadjuvant therapy has been given, as there is often a paucity of lymph nodes which 
are also smaller in size.[8]  
 
In cases where an inadequate number of nodes have been retrieved, it is common 
practice to return to the specimen and perform a secondary dissection to look for more 
nodes. We performed a study to compare the use of GEWF versus further fixation in 
formalin in terms of the number of nodes retrieved at secondary dissection, their size, 
and the rate of tumour upstaging.  
 
MATERIALS AND METHODS 
We undertook a controlled trial study design using randomisation, pseudoanonymisation 
and stratification.  Two hundred consecutive colorectal specimens received into the 
diagnostic histopathology department at Southampton General Hospital between June 
2012 and June 2014 were entered into the study.  A power calculation suggested that 
100 cases in each group would be sufficient to detect an extra three nodes with a power 
of 80%. 
 
Randomisation and anonymisation 
Samples were randomly allocated to either further fixation in formalin or GEWF.  The 
allocation was concealed from the chief investigator, as knowledge of allocation could 
have been a source of sample bias.[47]  Blinding was impossible because the 
intervention chemical was recognisable at secondary dissection via its distinctive smell 
and appearance.  Randomisation was performed using an automated randomisation 
programme.  Cards within sealed envelopes, containing the allocation information for 
each case were used.  Specimens were assigned a study number and 
pseudoanonymised, with a link maintained to the patient, in line with the Human Tissue 
Act, 2004, code of practice 1.[48]  Ethical approval was gained from North West 
Research Ethics Committee.  
 
Recruitment and stratification 
Only adenocarcinomas were considered for inclusion in the study. Cases were excluded 
if there was no informed patient consent for research; the tumour was a recurrence after 
previous resection; or a timely secondary dissection could not be performed.  Samples 
were stratified into either non-neoadjuvant or neoadjuvant therapy groups, because the 
use of long-course neoadjuvant therapy is known to be related to retrieval of fewer, 
smaller lymph nodes.[41,49]  Patients receiving short-course neoadjuvant therapy were 
placed into the non-neoadjuvant group.  Within each stratified group, samples were then 
randomly allocated into one of two intervention groups (Figure 1). 
 
Dissection and interpretation 
Specimens were fixed in formalin for 48-96 hours before primary dissection, which was 
performed by a variety of staff according to routine laboratory protocols.  Then, 
depending on the allocation, the specimen was placed in either fresh formalin or GEWF 
(glacial acetic acid 80ml, ethanol 500ml, water 150ml, formalin 80ml) for at least 24 
hours.  A secondary dissection was then performed by the chief investigator with the 
aim of sampling all residual lymph nodes. The number and sizes of nodes retrieved at 
primary and secondary dissections were recorded following microscopic examination.  
 
 
Statistical analysis 
As the data were approximately normally distributed (Figure 3), an independent 
samples t-test was used to compare the difference in number and size of lymph nodes 
between the two groups.  Mean differences are reported alongside 95% CI and p-
values. Statistical analysis was performed using IBM SPSS Statistics, version 21.[50] 
 
RESULTS 
Of the 200 patients recruited to the study, 119 (59.5%) were male and 81 (40.5%) were 
female. The mean age for all patients was 70.5 years (range 25 to 97). Pathological 
data are shown in Table 1. Thirty-nine percent of cancers were right sided whilst 61% 
were left sided or rectal.  Twenty-seven patients (13.5%) received long-course 
neoadjuvant therapy.  The two intervention chemicals were used almost equally (50.5% 
vs 49.5%).   
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Pathological data.  All secondary dissections were performed by the 
chief investigator. 
 
Factor (n=200) 
 
Variable Number  
(percentage / range) 
Site of tumour Caecum 38/200 (19.0%) 
 Ascending colon 18/200 (9.0%)  
 Hepatic flexure 7/200 (3.5%)  
 Transverse colon 11/200 (5.5%) 
 Splenic flexure 4/200 (2.0%)  
 Descending colon 9/200 (4.5%) 
 Sigmoid colon 49/200 (24.5%) 
 Rectum 64/200 (32.0%) 
Neoadjuvant therapy None 166/200 (83.0%)  
 Long course  27/200 (13.5%) 
 Short course
a 
 7/200 (3.5%) 
Dissector group for primary dissection Consultant (n=5) 66/200 (33.0%) 
 Advanced practitioner (n=1) 64/200 (32.0%) 
 Senior trainee
b
 (n=9) 48/200 (24.0%) 
 Junior trainee
c
 (n=7) 22/200 (11.0%) 
Mean time for primary dissection
d
  Overall 51 mins (14-150) 
 Consultant 32 mins(14-92) 
 Advanced practitioner 58 mins (25-105) 
 Senior trainee
b
 52 mins (15-110) 
 Junior trainee
c
 84 mins (30-150) 
Intervention chemical Further fixation 101/200 (50.5%) 
 GEWF 99/200 (49.5%) 
Mean time spent in intervention chemical Further fixation 25 hours (24-29) 
 GEWF 25 hours (24-32) 
Mean time for secondary dissection Further fixation 15.3 mins (4-45) 
 GEWF 15.2 mins (1-35) 
TNM classification (y)pT0 8/200 (4.0%) 
 (y)pT1 15/200 (7.5%) 
 (y)pT2 39/200 (19.5%) 
 (y)pT3 93/200 (46.5%) 
 (y)pT4 45/200 (22.5%) 
a
placed within the non-neoadjuvant group; 
b
in second year or more of histopathology training; 
c
in first year 
of histopathology training; 
d
not measured in 2/200 cases; 
e
not measured in 5/200 cases. 
 
The mean and median numbers of lymph nodes identified at primary dissection were 
19.3 and 18.0 respectively (Table 2).  The median number of lymph nodes retrieved at 
primary dissection for the neoadjuvant group was lower than that of the non-
neoadjuvant group (13 vs. 19).  The mean size of the smallest lymph nodes found at 
primary dissection was similar in both the neoadjuvant group (1.3mm) and the entire 
sample (1.5mm), although there was a difference in the mean size of the largest lymph 
nodes found at primary dissection between neoadjuvant group (5.6mm) and the entire 
sample (8.9mm).  
Table 2. Lymph nodes harvested at primary and secondary dissection for the entire sample and the subset in the 
neoadjuvant group.  
 
Primary dissection (n=200) Secondary dissection (n=200) 
 
Demographic Number  
(percentage / range) 
Demographic Number  
(percentage / range) 
 
 
Sample 
(n=200) 
 
Neoadjuvant 
(n=27) 
 
 Sample 
(n=200) 
Neoadjuvant 
(n=27) 
Total no. of nodes at primary 
dissection 
3850 379 Total no. of nodes at 
secondary dissection 
1555 171 
Mean no. of nodes at primary 
dissection 
19.3 (3-47) 14.0 (3-27) Mean no. of nodes at 
secondary dissection 
7.8 (0-30) 6.3 (0-18) 
Mean size of smallest- 
largest lymph nodes at 
primary dissection 
1.5-8.9mm (0.5-28.0) 1.3-5.6mm (0.5-10.0) Mean size of smallest-
largest nodes at secondary 
dissection 
1.2-4.1mm (0.5-12.0) 0.9-2.9mm (0.5-5.0) 
Median no. of nodes at 
primary dissection 
18 (3-47) 13 (3-27) No. of cases with no 
additional nodes at 
secondary dissection 
4 (2.0%) 2 (7.4%) 
No. of cases with only 
negative nodes at primary 
dissection 
121/200 (60.5%) 22/27 (81.5%) No. of cases with only 
negative nodes at 
secondary dissection  
177/200 (90.3%) 24/27 (96%) 
No. of negative nodes at 
primary dissection 
3561 361 No. of negative nodes at 
secondary dissection 
1526 169 
No. of cases with positive 
nodes at primary dissection 
79/200 (39.5%) 5/27 (18.5%) No. of cases with positive 
nodes at secondary 
dissection  
19/200 (9.7%) 1/27 (4.0%) 
No. of positive nodes at 
primary dissection  
289 18 No. of positive nodes at 
secondary dissection  
29 2 
Mean size of largest positive 
nodes at primary dissection  
8.6mm (1.0-28.0) 4.6mm (2.0-9.0) Mean size of largest 
positive nodes at 
secondary dissection 
4.4mm (1.5-8.0) 3.5mm (3.5-3.5) 
At secondary dissection 1555 additional lymph nodes were harvested, equating to a 
mean of 7.8 nodes per case overall, and a mean of 6.3 in the neoadjuvant group 
(Table 2).  In the non-neoadjuvant group the mean increase in number of lymph 
nodes retrieved was 49.9%.  In the neoadjuvant group this increased to 65.5%.  
When comparing further fixation and GEWF, there was no statistically significant 
difference in the number of lymph nodes retrieved at secondary dissection in either 
the entire sample (p=0.211) or the neoadjuvant group (p=0.614) (Table 3).   
 
Table 3. Statistical analysis with independent samples t-test. 
 
Entire sample (n=200) 
 
Research variable Further fixation 
[n =101(SD)] 
GEWF 
[n=99 (SD)] 
Mean difference 
(95% CI) 
P-value 
Mean no. of lymph nodes 8.27 (5.34) 7.25 (6.18) 1.02 (-0.58 - 2.63) 0.211 
Mean size of lymph nodes 2.56 (1.53) 2.43 (1.44) 0.13 (-0.02 - 0.27) 0.093 
 
Neoadjuvant group (n=27) 
 
Research variable Further fixation 
[n=15 (SD)] 
GEWF 
[n=12(SD)] 
Mean difference 
(95% CI) 
P-value 
Mean no. of lymph nodes 6.73 (4.32) 5.83 (4.82) 0.9 (-2.73 – 4.53) 0.614 
Mean size of lymph nodes 1.81 (1.04) 1.76 (1.0) 0.05 (-0.26 – 0.37) 0.730 
 
The mean size of the smallest lymph nodes found at secondary dissection was 
similar in both the neoadjuvant group (0.9mm) and the entire sample (1.2mm), 
although there was a difference in the mean size of the largest lymph nodes found at 
secondary dissection between the neoadjuvant group (2.9mm) and the entire sample 
(4.1mm) (Table 2).  When comparing further fixation and GEWF, there was minimal 
difference between the size of nodes found in either the entire sample (2.6mm with 
further fixation vs 2.4mm with GEWF) or neoadjuvant group (1.8mm for both 
interventions) (Table 4), with no statistically significant difference in the size of lymph 
nodes retrieved at secondary dissection in either the entire sample (p=0.093) or the 
neoadjuvant group (p=0.730) (Table 3). 
Table 4.  The effect of further fixation vs GEWF on the number and size of 
lymph nodes harvested at secondary dissection.  
 
 Sample (n=200) 
 
Neoadjuvant (n=27) 
 Further fixation 
(% / range) 
(n=101) 
GEWF 
(% / range) 
(n=99) 
 
Further 
fixation  
(% / range) 
GEWF  
(% / range) 
Total no. of nodes  837 718 101 70 
Mean no. of nodes  8.3 (0-28) 7.3 (0-30) 6.7 (0-13) 5.8 (0-18) 
Mean size of nodes  2.6mm  
(>0.2-12.0mm) 
2.4mm 
(>0.2-9.5mm) 
1.8mm 
(>0.2-5.0mm) 
1.8mm 
(>0.2-5.0mm) 
Negative nodes     
Total no. of negative nodes 828 698 99 70 
Mean size of negative nodes  2.6mm 
(>0.2-12.0mm) 
2.4mm 
(>0.2-9.5mm) 
1.8mm 
(>0.2-5.0mm) 
1.8mm 
(>0.2-5.0mm) 
No. of nodes ≥5.0mm  81/828 (9.8%) 51/698 (7.3%) 2/99 (2.0%) 1/70 (1.4%) 
No. of nodes ≥2.0-4.9mm 500/828 (60.4%) 399/698 (57.2%) 55/99 (55.6%) 31/70 (44.3%) 
No. of nodes >0.2-1.9mm 247/828 (29.8%) 248/698 (35.5%) 42/99 (42.4%) 38/70 (54.3%) 
Positive nodes     
Total no. of positive nodes 9 20 2 0 
Mean size of positive nodes  3.0mm  
(1.5-5.0mm) 
4.5mm  
(1.5-8.0mm) 
2.5mm 
(1.5-3.5mm) 
- 
No. of large metastases
a
  1/9 (11.1%) 9/20 (45.0%) 0/2 (0%) - 
No. of small metastases
b
  6/9 (66.7%) 9/20 (45.0%) 1/2 (50%) - 
No. of micrometastases
c
 2/9 (22.2%) 2/20 (10.0%) 1/2 (50%) - 
a
large metastases: ≥5.0mm; 
b
small metastases: ≥2.0-4.9mm; 
c
micrometastases:  >0.2mm-1.9mm. 
 
Fewer specimens elicited positive lymph nodes than at primary dissection (9.7% vs 
39.5%), with only 29 positive nodes identified at secondary dissection (Table 2).  
Most positive nodes were retrieved in the non-neoadjuvant cases (93.1%).   
 
The mean size of positive nodes identified at secondary dissection was smaller 
(Table 2).  The mean time spent performing the secondary dissection for each group 
was almost identical - 15.3 in the further fixation group vs 15.2 minutes in the GEWF 
group (Table 1).   
 
Upstaging that would lead to a possible change in treatment (pN0 to pN1/pN2) 
occurred in only two cases (1.0%), both of which were in the non-neoadjuvant group 
and had primary dissections performed by experienced dissectors.  The first case 
was in the GEWF group (primary nodal count 0/11).  Two of the 22 lymph nodes 
identified at secondary dissection were positive (4mm and 8mm in size), giving a 
final nodal count of 2/33.  The second case was in the further fixation group (primary 
nodal count 0/43). A further 12 nodes were identified at secondary dissection, and 
one of these was positive (3mm in size), giving a final nodal count of 1/55.   
 
There was a clearly detectable macroscopic difference between the two chemicals. 
GEWF made the fat nodular and hard, consistent with dehydration by the alcohol, 
making palpation for nodes more difficult. On the other hand, GEWF improved the 
visibility of lymph nodes as they became white in colour (Figure 2).  
 
DISCUSSION 
Secondary dissection resulted in the detection of more lymph nodes, in keeping with 
previous studies.[9,16,37-43,45-46]  We found that GEWF was not superior to 
formalin fixation in this respect. Only 29 (1.9%) of additional lymph nodes found at 
secondary dissection contained metastases; this small number may be a reflection of 
high quality underlying dissection practice, with staff meeting appropriate national 
standards[51-52] allowing  positive lymph nodes to be appropriately identified at 
primary dissection.  
 
The mean size of positive nodes identified at secondary dissection was smaller in 
the entire sample, and also in the neoadjuvant group - most likely because the larger 
positive nodes had already been identified at primary dissection.  Our findings are in 
keeping with previous studies which have described the retrieval of smaller lymph 
nodes in the specimens of patients who have received neoadjuvant therapy.[53-57]  
Nevertheless, the mean number of nodes retrieved at primary dissection in the 
neoadjuvant group achieved recommended targets in our study, contradicting the 
suggestion that the retrieval of 12 lymph nodes is unrealistic in these 
specimens,[49,54]  We found the target of 12 nodes is achievable without adjunct 
techniques, but relies upon high quality dissection practice; in our experience tiny 
lymph nodes may be identified in this way.  
 
Upstaging following secondary dissection from node negative (pN0) to node positive 
(pN1) was very infrequent, being observed in only two cases (1.0%).  Two previous 
studies found much higher levels of upstaging,[42-43]  but were small and open to 
detection and analysis bias, e.g. unclear statistical methodology.   
 
Although GEWF made nodes more visible, distinction between nodes and nodular 
fat or blood vessels by palpation was more difficult. In contrast, formalin is water-
based and so the fat remained soft.  Lymph nodes may not be so easily visible, but 
as only small lymph nodes remained in the fat at secondary dissection the ability to 
detect them by touch may have been more important in our specimens.  It is 
therefore essential that during training dissectors develop appropriate techniques in 
both vision and palpation in order to identify smaller nodes, as this may be important, 
especially for patients who have received long-course neoadjuvant therapy.  
 
This study attempted to remove and minimise bias, however, it was not entirely 
achievable.[58]  The main issue was the ability to detect the adjunct chemical, due to 
the distinctive smell and texture of GEWF making it instantly recognisable. It has to 
be accepted that potential bias from the secondary dissector could be introduced 
because blinding to the secondary fixation solution is not possible. However, the 
equivalence in the time spent on the secondary dissection for each adjunct chemical 
may be evidence that equal effort was used for each.  A further limitation of this 
study is the small size of the neoadjuvant group (n=27), which may put the findings 
at risk of type 1 statistical error. 
 
In conclusion, we have shown that secondary dissection retrieves more lymph 
nodes, irrespective of whether GEWF or formalin is used as the fixative. Although 
GEWF might be of benefit to practitioners who rely more on vision than palpation, we 
recommend further fixation in formalin in difficult cases – not only because it yields 
an equivalent number of lymph nodes, but also because it is cheaper, easier to 
prepare and more readily available. Furthermore, adequate fixation combined with 
high quality training of staff and an appropriate time spent retrieving lymph nodes 
should allow standards to be achieved without the need for adjunct techniques in the 
great majority of cases.   
 
TAKE HOME MESSAGES 
GEWF is no better than further fixation in formalin in terms of number and size of 
lymph nodes harvested at secondary dissection.  
 
The use of adjunct techniques followed by secondary dissection only leads to 
upstaging in a small percentage of cases, but in these it may be clinically significant. 
 
Adjunct techniques are not required in the majority of cases if an appropriate primary 
dissection has been performed on an adequately fixed specimen by an appropriately 
trained person who spends appropriate time performing the task. 
 
In difficult cases adjunct techniques and/or a secondary dissection may be useful, 
but further fixation in formalin is recommended as it is cheaper, more readily 
available and more efficient at detecting lymph nodes. 
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Figure 1. Groups within the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LN – lymph node; A – adipose tissue; BV – blood vessel. 
Figure 2.  Characteristic white colour of lymph nodes after GEWF use. 
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Figure 3.  Normal distribution plots of data.
 
a. no. of additional nodes at secondary dissection (all cases); b. no. of additional nodes at 
secondary dissection (neoadjuvant cases); c. size of nodes at secondary dissection (all 
cases); d. size of nodes at secondary dissection (neoadjuvant cases). 
 
